Business And Finance News, In Brief
Executive Summary
Study Finds Personalized Medicine Increasingly Emphasized In Oncology
You may also be interested in...
Eisai Makes Oncology Debut With Halaven, But Development Question Marks Remain
TOKYO - Eisai gained its first U.S. approval for one of its in-house developed oncology products, Halaven (eribulin), but the company's blockbuster expectations may be tempered by progression-free survival data that did not meet secondary endpoints
FDA's Seyfert-Margolis On Companion Diagnostics Guidance
Industry is anxiously awaiting guidance from FDA on the development of companion diagnostics for drugs that will inform efforts to move towards personalized medicine.
Finding Inspiration: Ipsen Builds Fourth Specialist Franchise With Hemophilia Deal
Deal in some ways mirrors Ipsen's July 2006 agreement with Tercica in endocrinology.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: